COMMUNIQUÉS West-GlobeNewswire

Augustine Therapeutics appoints Rie Schultz Hansen, PhD as Chief Scientific Officer and establishes Copenhagen-based subsidiary
21/05/2025
Augustine Therapeutics appoints Rie Schultz Hansen, PhD as Chief Scientific Officer and establishes Copenhagen-based subsidiary New recruit expands senior team capabilities as the business progresses its lead HDAC6 [...]
Rapport Therapeutics to Host 2025 Investor and Analyst Day
21/05/2025
BOSTON and SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines [...]
Tonix Pharmaceuticals Announces First Patient Dosed in Phase 2 OASIS Study of TNX-102 SL for Reduction of Acute Stress Reaction
21/05/2025
Investigator-initiated Phase 2 trial to evaluate TNX-102 SL’s potential to reduce severity of acute stress reaction (ASR) and frequency of acute stress disorder (ASD) Trial is sponsored by the University of North [...]
Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference
21/05/2025
MENLO PARK, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed to set a new standard for the treatment [...]
Castle Biosciences to Present at the 2025 Jefferies Global Healthcare Conference
21/05/2025
FRIENDSWOOD, Texas, May 21, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is [...]
NeurAxis Announces $5.0 Million Registered Direct Offering
21/05/2025
CARMEL, Ind., May 21, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and [...]
GenVivo Highlights Non-Integrating Retroviral Vector Technology with Persistent Payload Expression at the 2025 Retroviruses Meeting
21/05/2025
Retroviral vectors that are both non-replicating and non-integrating represent a novel and attractive tool that has potential advantages for gene delivery therapy, immunotherapy, and vaccinology. SAN MARINO, Calif., May [...]
Coave Therapeutics Establishes New Scientific Advisory Board to Accelerate Innovation in Genetic Medicines for Eye and CNS Diseases
21/05/2025
Paris, France – May 21, 2025 – Coave Therapeutics (‘Coave’), a company pioneering the future of genetic medicines, today announces the evolution of its Scientific Advisory Board (SAB). This renewed SAB reflects Coave’s [...]
Verona Pharma Announces June 2025 Investor Conference Participation
21/05/2025
LONDON and RALEIGH, N.C., May 21, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will participate in fireside chats at the following [...]
Biodesix to Participate in Upcoming Investor Conferences
21/05/2025
LOUISVILLE, Colo., May 21, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that members of the Biodesix management team, will participate in two upcoming [...]
Curium and NRG PALLAS extend collaboration in the supply of essential medical isotope to hospitals
21/05/2025
Global supply of technetium-99m, most widely used medical isotopes in nuclear medicine, is secured for the coming years PETTEN, The Netherlands, May 21, 2025 (GLOBE NEWSWIRE) -- NRG PALLAS and Curium have extended their [...]
EuroPCR 2025: Late-Breaking Data Demonstrate Sustained Significantly Lower Event Rates With Elixir Medical’s DynamX Bioadaptor Over Drug-Eluting Stent Through Three Years
21/05/2025
Paris, May 21, 2025 (GLOBE NEWSWIRE) -- —Sustained durability of treatment effect with significantly lower TLF rates (2.7% versus 7.2%, p=0.030) with DynamX ® compared to DES— —Significantly lower rate of Cardiac Death [...]
EuroPCR 2025 : Des données récentes démontrent une réduction durable et statistiquement significative des taux d’événements avec le bioadaptateur DynamX® d’Elixir Medical par rapport au stent à élution médicamenteuse (SEM) sur trois ans
21/05/2025
Paris, 21 mai 2025 (GLOBE NEWSWIRE) -- —Un effet thérapeutique durable avec des taux de TLF significativement inférieurs (2,7 % contre 7,2 %, p = 0,030) avec DynamX ® par rapport au SEM— —Taux de décès cardiaque [...]
Belite Bio Announces FDA Granting of Breakthrough Therapy Designation for Tinlarebant for the Treatment of Stargardt Disease
21/05/2025
Designation is based on the pivotal Phase 3 DRAGON trial interim analysis results demonstrating Tinlarebant’s efficacy and favorable safety profile Trial completion expected by Q4 2025 (including a three-month follow-up [...]
Juvenescence closes $76m first tranche of Series B-1 financing led by Abu Dhabi’s M42 alongside strategic partnership
21/05/2025
Juvenescence closes $76m first tranche of Series B-1 financing led by Abu Dhabi’s M42 alongside strategic partnership Close of $76m Series B-1 tranche follows recent announcement of groundbreaking strategic partnership [...]
ONWARD Medical Advances Brain-Computer Interface Leadership with Fourth and Fifth Successful BCI Implants
21/05/2025
Groundbreaking procedures extend ONWARD’s leadership in the rapidly emerging brain-computer interface (BCI) field ARC-BCI Therapy is designed to restore thought-driven movement after spinal cord injury and other [...]
Augustine Therapeutics appoints Rie Schultz Hansen, PhD as Chief Scientific Officer and establishes Copenhagen-based subsidiary
21/05/2025
Augustine Therapeutics appoints Rie Schultz Hansen, PhD as Chief Scientific Officer and establishes Copenhagen-based subsidiary New recruit expands senior team capabilities as the business progresses its lead HDAC6 [...]
New funds secured – allowing the commercial ramp-up of QUVIVIQ to accelerate Idorsia’s path to profitability
21/05/2025
Ad hoc announcement pursuant to Art. 53 LR CHF 150 million new money facility from bondholders now implemented and providing cash runway to mid-2026 Holistic convertible debt restructuring progressing with bondholder [...]
IBA and PET Pharm Bio sign contract to install a Cyclone® IKON in Taiwan
21/05/2025
The Cyclone ® IKON is IBA’s high energy and high-capacity cyclotron which offers the largest energy spectrum for the production of PET and SPECT isotopes from 13 MeV to 30 MeV Louvain-La-Neuve, Belgium, May 21, 2025 – [...]

Pages